相关实验视频
Updated: Mar 3, 2026

09:12
Nanoparticle-mediated siRNA Gene-silencing in Adult Zebrafish Heart
Published on: July 29, 2018
8.6K
齐勒贝西兰:一种RNA干扰剂 - 它的需要和潜力是改变高血压治疗的可能性
Sajeet Verma1, Akshyaya Pradhan2, Prashant Thandi1
1Department of Cardiology, King George's Medical University, Lucknow, India.
概括
齐勒贝西兰是一种新的RNA干扰 (RNAi) 疗法,在不频繁的剂量下显著降低血压. 这种创新的高血压治疗方法可以改善血压的坚持并降低心血管风险.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 在RNA治疗方面,RNA疗法.
背景情况:
- 高血压是心血管疾病的主要可修改风险因素,许多患者无法达到目标血压.
- 目前的治疗方法面临着诸如不良坚持,治疗惯性和复杂的剂量计划等挑战.
- 氨酸- ангиотензин- алдостерон系统 (RAAS) 对于血压调节至关重要;长期封锁可以降低心血管风险.
研究的目的:
- 为了评估zilebesiran的疗效和安全性,RNA干扰 (RNAi) 治疗向血管酶原 (AGT).
- 评估不频繁用药的潜力,以改善粘附性并实现持续的血压控制.
- 使用RNAi技术探索高血压管理的新前沿.
主要方法:
- 齐勒贝西兰是一种GalNAc结合的siRNA,通过亚亚糖蛋白受体介导传递准肝脏AGTmRNA.
- 皮下注射导致循环AGT和血管新生素II的持续减少.
- 阶段I,II,KARDIA-1和KARDIA-2试验评估了AGT抑制,降低血压,安全性和耐受性.
主要成果:
- 齐勒贝西兰实现了>90%的AGT抑制和显著的24小时缩血压降低 (-10~-27mmHg).
- 该疗法在KARDIA-1和KARDIA-2研究中显示出作为单一疗法和辅助疗法的持续疗效.
- 观察到有利的安全性和耐受性,没有严重的脏或电解质障碍.
结论:
- 齐勒贝西兰每年两次的剂量可以通过增强坚持和确保持续的血压控制来重新定义高血压的管理.
- 这种RNAi疗法有可能降低高血压患者的心血管风险.
- 目前正在进行的III期试验将进一步阐明其长期疗效,安全性和在不同人群中的适用性.
更多相关视频
相关概念视频
Antihypertensive Drugs: Direct Renin Inhibitors
1.6K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
siRNA - Small Interfering RNAs
18.9K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.9K
Experimental RNAi
8.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.1K
Antihypertensive Drugs: Thiazide-Class Diuretics
2.0K
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
2.0K
RNA Interference
28.3K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.3K

